Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Cash & Equivalents (2016 - 2025)

Vanda Pharmaceuticals' Cash & Equivalents history spans 17 years, with the latest figure at $84.9 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 17.07% to $84.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $84.9 million, a 17.07% decrease, with the full-year FY2025 number at $84.9 million, down 17.07% from a year prior.
  • Cash & Equivalents hit $84.9 million in Q4 2025 for Vanda Pharmaceuticals, up from $70.0 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for VNDA hit a ceiling of $354.2 million in Q1 2023 and a floor of $49.4 million in Q3 2022.
  • Historically, Cash & Equivalents has averaged $107.2 million across 5 years, with a median of $92.7 million in 2024.
  • Biggest five-year swings in Cash & Equivalents: soared 429.19% in 2023 and later tumbled 64.66% in 2024.
  • Tracing VNDA's Cash & Equivalents over 5 years: stood at $52.1 million in 2021, then soared by 159.32% to $135.0 million in 2022, then rose by 0.59% to $135.8 million in 2023, then fell by 24.67% to $102.3 million in 2024, then fell by 17.07% to $84.9 million in 2025.
  • Business Quant data shows Cash & Equivalents for VNDA at $84.9 million in Q4 2025, $70.0 million in Q3 2025, and $81.0 million in Q2 2025.